Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

BACKGROUND: Triweekly capecitabine plus irinotecan (CAPIRI) was not a replacement for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the treatment of metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. Recently, it has reported that mCAPIRI is well tolerated and...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J Clin Oncol
Главные авторы: Suzuki, Nobuaki, Hazama, Shoichi, Nagasaka, Takeshi, Tanioka, Hiroaki, Iwamoto, Yasuo, Negoro, Yuji, Yamauchi, Masami, Kobayashi, Michiya, Okuda, Hiroshi, Fujishima, Noriaki, Nishimura, Taku, Yamanaka, Naoki, Toyota, Kazuhiro, Mori, Yoshiko, Nakagami, Yuki, Shimokawa, Mototsugu, Nagano, Hiroaki, Okajima, Masazumi
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Singapore 2019
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6736909/
https://ncbi.nlm.nih.gov/pubmed/31144145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-019-01473-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы